IL308951A - Inhibitors of proton tyrosine kinase and methods of using them - Google Patents

Inhibitors of proton tyrosine kinase and methods of using them

Info

Publication number
IL308951A
IL308951A IL308951A IL30895123A IL308951A IL 308951 A IL308951 A IL 308951A IL 308951 A IL308951 A IL 308951A IL 30895123 A IL30895123 A IL 30895123A IL 308951 A IL308951 A IL 308951A
Authority
IL
Israel
Prior art keywords
bruton
inhibitors
methods
tyrosine kinase
tyrosine
Prior art date
Application number
IL308951A
Other languages
English (en)
Hebrew (he)
Inventor
Sriram Balasubramanian
Ivo Cornelissen
Yue Guo
Jocelyn H Leu
Kathryn E Packman
James Alexander Palmer
Ulrike Philippar
Navin Rao
Mark S Tichenor
Jennifer D Venable
John J M Wiener
Xin Miao
Original Assignee
Janssen Pharmaceutica Nv
Sriram Balasubramanian
Ivo Cornelissen
Yue Guo
Jocelyn H Leu
Kathryn E Packman
James Alexander Palmer
Ulrike Philippar
Navin Rao
Mark S Tichenor
Jennifer D Venable
John J M Wiener
Xin Miao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Sriram Balasubramanian, Ivo Cornelissen, Yue Guo, Jocelyn H Leu, Kathryn E Packman, James Alexander Palmer, Ulrike Philippar, Navin Rao, Mark S Tichenor, Jennifer D Venable, John J M Wiener, Xin Miao filed Critical Janssen Pharmaceutica Nv
Publication of IL308951A publication Critical patent/IL308951A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL308951A 2021-06-04 2022-06-02 Inhibitors of proton tyrosine kinase and methods of using them IL308951A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163196843P 2021-06-04 2021-06-04
PCT/IB2022/055154 WO2022254371A1 (en) 2021-06-04 2022-06-02 Inhibitors of bruton's tyrosine kinase and methods of their use

Publications (1)

Publication Number Publication Date
IL308951A true IL308951A (en) 2024-01-01

Family

ID=82214195

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308951A IL308951A (en) 2021-06-04 2022-06-02 Inhibitors of proton tyrosine kinase and methods of using them

Country Status (14)

Country Link
US (1) US12622910B2 (enExample)
EP (1) EP4346834A1 (enExample)
JP (1) JP2024520630A (enExample)
KR (1) KR20240019214A (enExample)
CN (1) CN117412753A (enExample)
AU (1) AU2022284369A1 (enExample)
BR (1) BR112023025459A2 (enExample)
CA (1) CA3220015A1 (enExample)
CL (2) CL2023003564A1 (enExample)
IL (1) IL308951A (enExample)
JO (1) JOP20230310A1 (enExample)
MX (1) MX2023014435A (enExample)
TW (1) TW202317127A (enExample)
WO (1) WO2022254371A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11964976B1 (en) 2023-09-12 2024-04-23 King Faisal University Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-c][1,6]naphthyridines as CK2 inhibitors
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US4886646A (en) 1988-03-23 1989-12-12 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Hanging drop crystal growth apparatus and method
US5096676A (en) 1989-01-27 1992-03-17 Mcpherson Alexander Crystal growing apparatus
US5130105A (en) 1990-10-23 1992-07-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Protein crystal growth tray assembly
US5221410A (en) 1991-10-09 1993-06-22 Schering Corporation Crystal forming device
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
US5400741A (en) 1993-05-21 1995-03-28 Medical Foundation Of Buffalo, Inc. Device for growing crystals
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
AU2005284796A1 (en) 2004-09-15 2006-03-23 Janssen Pharmaceutica, N.V. Thiazolopyridine kinase inhibitors
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
US7605154B2 (en) 2005-08-08 2009-10-20 Janssen Pharmaceutica N.V. Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
US7427625B2 (en) 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
EP2471789B9 (en) 2009-08-26 2015-03-25 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
JP2015536446A (ja) 2012-10-11 2015-12-21 ファーマサイクリックス，インク． Ｔｅｃファミリーキナーゼ阻害剤療法のためのコンパニオン診断
EP2970291B1 (en) 2013-03-15 2022-05-11 Janssen Pharmaceutica, N.V. Processes and intermediates for preparing a medicament
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
WO2015127261A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
BR112017001677A2 (pt) 2014-08-01 2018-07-17 Pharmacyclics Llc biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk
SMT202100674T1 (it) * 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103060A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
JP2023522957A (ja) 2020-04-21 2023-06-01 フラッグシップ パイオニアリング， インコーポレイテッド 二機能性分子およびその使用方法
MX2024010134A (es) 2022-02-18 2024-08-27 Janssen Pharmaceutica Nv Sintesis de inhibidores de tirosina quinasa de bruton.

Also Published As

Publication number Publication date
WO2022254371A1 (en) 2022-12-08
US12622910B2 (en) 2026-05-12
CL2023003564A1 (es) 2024-06-21
EP4346834A1 (en) 2024-04-10
TW202317127A (zh) 2023-05-01
BR112023025459A2 (pt) 2024-02-27
US20230013755A1 (en) 2023-01-19
CN117412753A (zh) 2024-01-16
JP2024520630A (ja) 2024-05-24
JOP20230310A1 (ar) 2023-11-29
MX2023014435A (es) 2024-03-08
AU2022284369A1 (en) 2024-01-25
CA3220015A1 (en) 2022-12-08
KR20240019214A (ko) 2024-02-14
CL2024002895A1 (es) 2025-02-14

Similar Documents

Publication Publication Date Title
IL297625B2 (en) PI3K-alpha inhibitors and methods of using them
SG11202109067PA (en) Protein tyrosine phosphatase inhibitors and methods of use thereof
IL310547A (en) Alkyl substituted ribose derivatives in the '1 position and methods of use
IL259862B (en) Inhibitors of proton tyrosine kinase and methods of using them
ZA201903932B (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
IL279587A (en) Protein tyrosine phosphatase inhibitors and methods of using them
SI4084778T1 (sl) Formulacije inhibitorja amorfne kinaze in načini njihove uporabe
IL288996B2 (en) Aminopyrimidine amide autophagy inhibitors and methods of using them
IL312348A (en) HIF-2ALPHA inhibitors and methods of using it
PL3972604T3 (pl) Inhibitor kinazy tyrozynowej brutona do zastosowania w leczeniu przewlekłej pokrzywki spontanicznej
EP2073811A4 (en) KINASEHEMMER FOR THE TREATMENT OF MYLEOPROLIFERATIVE AND OTHER PROLIFERATIVE DISEASES
IL264854A (en) Spt5 inhibitors and methods of use thereof
IL264341A (en) Succinate forms and preparations of proton tyrosine kinase inhibitors
IL319748A (en) PCSK9 inhibitors and methods of using them
IL313417A (en) Anti-RAF kinases and methods of using them
IL308152A (en) 2-fluoroalkyl-4,3,1-oxadiazol-5-yl-thiazole, HDAC6 inhibitors for use in the treatment of metabolic disease and HFPEF
PL3972603T3 (pl) Sposoby leczenia zespołu sjögrena przy użyciu inhibitora kinazy tyrozynowej brutona
IL288924A (en) Casein kinase 1 inhibitors for use in the treatment of diseases associated with the expression of dux4 such as muscular dystrophy and cancer
PL4188402T3 (pl) Kompozycje probiotyczne i ich zastosowanie w zapobieganiu i/lub leczeniu chorób i/lub zaburzeń skóry
BR112023025459A2 (pt) Inibidores da tirosina quinase de bruton e métodos de uso dos mesmos
IL312466A (en) PI3K-alpha inhibitors and methods for their preparation and use
IL326776A (en) Combinations comprising bcr:abl-1 inhibitor and a second tyrosine kinase inhibitor for use in the treatment of cancer
IL327476A (en) Modified oligonucleotides and methods for using them
HK40108993A (en) Inhibitors of bruton's tyrosine kinase and methods of their use
EP4444309A4 (en) PYRIMIDINS AND THEIR METHODS OF USE